Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AZ/Merck & Co' s Lynparza Gets US Approval For Prostate Cancer

Days After Green Light For Clovis's Rival PARP

Executive Summary

Lynparza has received the green light from the FDA for advanced prostate cancer, its fourth tumor type, and while it may not be the first PARP inhibitor to be approved for this indication, analysts are expecting the drug to lead the class.

You may also be interested in...



AstraZeneca Partners With AmoyDx On Companion Diagnostics For Lynparza

Teaming again with the Shanghai biotech, AstraZeneca will seek assays that can be incorporated into companion diagnostics for Lynparza in prostate and breast cancer.

AstraZeneca Partners With AmoyDx On Companion Diagnostics For Lynparza

Deal Snapshot: Teaming again with the Shanghai biotech, AstraZeneca will seek assays that can be incorporated into companion diagnostics for Lynparza in prostate and breast cancer.

From Loser To Leader: The Turnaround Of AstraZeneca

Recently AstraZeneca became the most valuable company by market capitalization on the FTSE 100, quite a switch in fortunes from earlier in the decade, and HR head Fiona Cicconi tells Scrip that a change in culture as well as a productive pipeline has contributed to the firm's recent success.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC142261

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel